CCL4 and B-cell non-Hodgkin lymphoma: Moreover, evaluation of the CCL3 and CCL4 levels may be helpful for selecting B-cell lymphoma patients likely to benefit from doxorubicin treatment in combination with the velcade or ibrutinib [60].